STAT3 and posterior cortical atrophy: Therefore, this descriptive study aimed to examine the expression and activity of STAT3, STAT5, and STAT6 in PCa patients undergoing systemic therapies, including ADT, enzalutamide, abiraterone, and docetaxel.